Document is current

Article History

Received: 2 October 2024

Accepted: 11 March 2025

First Online: 20 March 2025

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that the research was carried out in the absence of any commercial or financial relationship that could be interpreted as a potential conflict of interest. Several authors of these guidelines, including voting members, have interacted with the pharmaceutical industry including the manufacturers of some of the drugs mentioned in these recommendations. However, none of the authors received any support or fee directly or indirectly related to or influencing the development of these guidelines. AKGM received speaker fees and consulting from Abbvie, Johnson & Johnson. AMK received consuting fees from Abbvie, Lilly, UCB, Organon, and Janssen. CF received speaker fees from Takeda, Janssen, Abbvie, Amgen, Organon. ESP received speaker fees and consulting from Abbvie, Novartis, Lilly, Johnson & Johnson. JSC received speaker fees from GSK and Janssen. KLLLM received speaker fees and consulting from Novartis and Johnson & Johnson. LAC received speaker fees and consulting from Johnson & Johnson, Takeda, Abbvie. LDAV received speaker fees and consulting from Novartis, Johnson & Johnson. LMHM received speaker fees and consulting from Johnson & Johnson, Abbvie, Pfizer, Novartis, Amgen, Organon, Celltrion, UCB. MFBRG received speaker fees and consulting from Johnson & Johnson, Abbvie, Amgen, Lilly, UCB. MIBFL received speaker fees and consulting from Abbvie, Novartis, Takeda, Johnson & Johnson. MMP received consuting fees from Abbvie, Lilly and Janssen. RMX received Speaker fees, consulting, research funding from Abbvie, Pfizer, Amgen, Biogen, Novartis, Janssen, UCB. RR is/has served as a scientific consultant, speaker, or clinical study investigator for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Galderma, Janssen-Cilag, Eli-Lilly, Leo-Pharma, Novartis, Pfizer, Sanofi, and UCB. RSH received speaker fees and consulting from Abbvie, Novartis, Takeda, Johnson & Johnson. OAM received consulting fees from AstraZeneca and GSK; received payment or honoraria for lectures or presentations from AbbVie, Janssen, GSK, UCB and AstraZeneca; and participated in a data safety monitoring board or advisory board for GSK, CellTrion, Bristol, Novartis, Janssen, and AstraZeneca. VAS received speaker fees and consulting from Abbvie, Novartis, Lilly, Johnson & Johnson, GSK, Astrazeneca. VFA received speaker fees, consulting, clinical researches from Celltiron, Amgen, Janssen, Organon, Sandoz, Abbvie, Fresenius Kabi, Takeda, LG, Boehringer-Ingelheim, Bristol Myers-Squibb, GSK, AstraZeneca. The authors not mentioned above declare no competing interests.